Aripiprazole in the real-world treatment for irritability associated with autism spectrum disorder in children and adolescents in Japan: 52-week post-marketing surveillance.

Interestingly, based on multiple regression analysis, comorbid ADHD was not selected as the variable affecting the ABC-J irritability subscale score at end-point (see Additional file 2 ). From the results of the improvement assessment by CGI-I, the percentage of patients scoring 3 ‘minimally improved’ or less was 74.3% ( n = 306/412) at week 4, 79.4% ( n = 342/431) to 85.4% ( n = 239/280) after week 8, and 77.0% ( n = 376/488) at end-point (LOCF), with an increasing trend throughout the treatment period (see Additional file 3 ).

also in 63,971 other papers